Fig. 7: ECM1-HF-MSCs show a better effect in LC treatment through inhibiting the activation of HSCs and the TGF-β/Smad signaling pathway in vivo. | Cell Death Discovery

Fig. 7: ECM1-HF-MSCs show a better effect in LC treatment through inhibiting the activation of HSCs and the TGF-β/Smad signaling pathway in vivo.

From: ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway

Fig. 7: ECM1-HF-MSCs show a better effect in LC treatment through inhibiting the activation of HSCs and the TGF-β/Smad signaling pathway in vivo.

A, B HE and Masson staining in each group. Scale bar = 100  μm. C Area of collagen fibers in each group. D Ishak scores show the degree of LC in all groups. E–G Changes in the serological indices of ALT, AST and ALP. H–K Western blotting and semiquantitative analysis of a-SMA, p-Smad2/3, and TGF-β in all groups. Data are shown as the means ± SDs (*p  <  0.05, **p <  0.01, ***p  <  0.001).

Back to article page